Biotherapeutics News: Breaking Biotherapeutics News, Comments and Articles. - Page: 5

Third Rock Ventures Raises $516 Million Fund III

Third Rock Ventures, LLC, a venture capital firm focused on building healthcare companies, today announced the final closing of Fund III, raising $516 million in an oversubscribed fund. With Fund III, Third Rock will continue to execute on its strategy of launching, building and supporting transformative healthcare companies. Since its inception, Third Roc...

APO-T and LinXis Announce Antibody Drug Conjugate Option to in-License Agreement

APO-T B.V. and LinXis B.V., both privately owned oncology companies, announced today that LinXis has granted APO-T an exclusive worldwide license for the development and commercialization of fully-human antibody-drug-conjugates using APO-T’s MAGE-HLA targeted antibodies and LinXis’ unique LX linker technology. In exchange, LinXis will receive milestone...

ZOLL Honored for Excellence in Customer Satisfaction for 12th Consecutive Year

ZOLL® Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it is the only company to receive the NorthFace ScoreBoard AwardSM for “world class” excellence in customer satisfaction for the 12th consecutive year. The 12-year designation was awarded to ZOLL for excellence in technical support. The...

Dendritic cell production patent is awarded to NW Bio

Northwest Biotherapeutics obtained a U.S. patent for technology involving the production of human dendritic cells.  -More- 

Liquid Chromatography System Enhances Biopharmaceutical Workflows

Thermo Fisher Scientific Inc. featured its Dionex UltiMate 3000 biocompatible rapid separation (BioRS) liquid chromatography system at Pittcon 2013. The system is designed to combine the performance advantages of ultrahigh-performance liquid chromato...

NW Bio bags US patent to manufacture human dentric cells

Northwest Biotherapeutics (NW Bio), a US-based biotechnology company, has received a US patent for a process to manufacture human dendritic cells.

Pfizer and Protalix' Gaucher drug Uplyso approved in Brazil

US drugs behemoth Pfizer (NYSE: PFE) and Israel-based Protalix BioTherapeutics (NYSE MKT:PLX) said that the Brazilian National Health Surveillance Agency (ANVISA) has granted regulatory approval to Uplyso (alfataliglicerase) for the long-term enzyme...

NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference

BETHESDA, Md., March 19, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers, the Company's Chairman and Chief Executive Officer, will be presenting at the 25th Annual ROTH Conference at 8:30 a.m. PDT on Wednesday, March 20, 2013, at the Rit...

Pfizer, Protalix type I Gaucher disease drug Uplyso gets Brazilian approval

Pfizer and Protalix BioTherapeutics have obtained approval from the Brazilian National Health Surveillance Agency for Uplyso (alfataliglicerase) as type I Gaucher disease therapy.

Oxygen Biotherapeutics Reports Financial Results for the Third Quarter FY2013

Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a development stage biomedical company focused on developing oxygen-carrying intravenous and topical products, today announced financial results for the three and nine month periods ending January 31, 2013. Third Quarter 2013 Financial Snapshot Cash and cash equivalents were $0.8 milli...

NW Bio Receives U.S. Patent On Broad Processes For Producing More Potent Dendritic Cells

BETHESDA, Md., March 18, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has been issued a key U.S. patent (#8389278) covering novel processes for manufacturing human dendritic cells.  The cells produced through these processes are much more pot...

Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013

Mentor Capital, Inc. (Pink Sheets:MNTR) reports that for 2013 it has added Galena Biopharma Corporation (NASDAQ:GALE), NewLink Genetics Corporation (NASDAQ:NLNK), Vical Incorporated (NASDAQ:VICL) and Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) to its proprietary Cancer Immunotherapy Index. The four firms and others in the Index represent the second generat...

FDA Grants Orphan-Drug Designation to ProMetic's Plasma-Derived Plasminogen Drug

ProMetic Life Sciences Inc. announced today that an orphan drug designation status has been granted for its plasma purified human plasminogen drug to ProMetic BioTherapeutics, Inc., its US based subsidiary, by the FDA. The orphan drug designation is...

US FDA Grants Orphan-Drug Designation to ProMetic's Plasma-Derived Plasminogen Drug

LAVAL, QUEBEC and ROCKVILLE, MARYLAND and TAIPEI, TAIWAN -- (Marketwire) -- 03/14/13 -- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic" or the "Corporation") announced today that an orphan drug designation status has been granted for its plasma purified human plasminogen drug to ProMetic BioTherapeutics, Inc., its US based subsidiary, by the American Food and Drug Administration ("FDA"). The...

Q Therapeutics Appoints Diane Jorkasky, MD, to Board of Directors

SALT LAKE CITY, UT -- (Marketwire) -- 03/14/13 -- Q Therapeutics, Inc. today announced the appointment of Diane Jorkasky, M.D., FACP, as an independent member of its Board of Directors. Dr. Jorkasky will assume the board seat formerly held by Joydeep Goswami, Ph.D., President of Life Technologies, Japan. With the addition of Dr. Jorkasky to Q Therapeutics' Board, the number of directors remains...

Oxygen Biotherapeutics Announces Third Quarter FY2013 Financial Results Conference Call and Webcast

Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) today announced that the Company plans to report third quarter fiscal year 2013 financial results on Form 10-Q on Monday, March 18, 2013. Oxygen’s President and Chief Financial Officer Michael Jebsen will host a conference call and live webcast to discuss the results on Tuesday, March 19, 2013, at 11 a.m. EDT....

Engineering Stream Conferences at PEGS 2013

FARMINGTON, Conn., March 13, 2013 /PRNewswire-iReach/ -- Tools for engineering the next generation of antibodies and biologics will need to address the current challenges facing the industry. These include tapping into innovative ideas for developing antibodies against intracellular and membrane targets, engineering bispecific constructs, and designing antibodies for infectious disease and CNS app...

NW Bio to expand cross-border supply of brain cancer product DCVax-L

US-based Northwest Biotherapeutics (NW Bio) and its partners have obtained the necessary regulatory and institutional approvals in both Germany and the UK to expand the scope of the manufacturing in Germany of the company's DCVax-L product for brain...

Dyax Corp. to Participate in the 25th Annual ROTH Conference

Dyax Corp. (NASDAQ: DYAX) announced today that the Company will participate in the 25th Annual ROTH Conference, being held March 17-20, 2013, at the Ritz-Carlton Laguna Niguel in Dana Point, CA. Gustav Christensen, President and Chief Executive Officer of Dyax, will present on Tuesday, March 19 at 5:30 PM (PT). Mr. Christensen will provide a corpora...

NW Bio Establishes Cross-Border Manufacturing And Distribution For DCVax® In Europe

BETHESDA, Md., March 12, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Company has taken a key step in building Europe-wide arrangements for manufacturing and distribution of DCVax.  This represents a major area of competitive differenti...

Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit

Baltimore, MD (PRWEB) March 12, 2013 Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Genedata Expressionist® for Mass Spectrometry will be showcased in the “E...

How to select the best candidate for biotherapeutics drug development

Antibodies, antibody-like proteins, and other biotherapeutics represent a large and growing number of molecular entities entering human clinical trials in virtually all disease indications. The [...]

[ProMetic], [Hematech] sign alliance for orphan drug development

Canadian pharmaco [ProMetic Life Sciences Inc.] (cancer and hematology therapeutics) has granted private Taiwanese company [Hematech Biotherapeutics Inc.] (hematology) a global co-exclusive development license (excluding China) to an undisclosed plas...

ZOLL Wins Patent Infringement Case Against ELan Med GmbH

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that the District Court of Munich, Germany, ruled in favor of ZOLL in granting an injunction against ELan Med GmbH of Cologne, Germany, for infringing on a ZOLL patent through the distribution and sale of certain ELan products for use with ZOLL’s I...

Company Profile for BioCardia, Inc.

BioCardia was founded in 1999 to enable biointerventional cardiology and is headquartered in San Carlos, California. BioCardia's Helix Biotherapeutic Delivery business remains committed to being the platform of choice for delivery of therapeutic agents to the myocardium. Novel biotherapeutic approaches have enormous promise in addressing unmet cli...